Dynavax Technologies (DVAX)
(Delayed Data from NSDQ)
$10.60 USD
-0.38 (-3.46%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $10.60 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DVAX 10.60 -0.38(-3.46%)
Will DVAX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for DVAX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DVAX
New Strong Sell Stocks for July 9th
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
DVAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates
Dynavax Technologies (DVAX) Reports Break-Even Earnings for Q4
Pacira (PCRX) Preliminary '23 Revenues Solid, Exparel Strong
Other News for DVAX
Dynavax’s Promising Vaccine Trials and Financial Outlook Merit a Buy Rating
Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program
Dynavax Technologies (NASDAQ:DVAX): A Promising Biopharma Option Despite Recent Challenges
Dynavax doses first patient in Phase 1/2 clinical trial evaluating Z-1018
Biotech Alert: Searches spiking for these stocks today